Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / In-depth proteomic analysis of non-small cell lung cancer to discover molecular targets and candidate biomarkers
Not an EDRN Protocol

In-depth proteomic analysis of non-small cell lung cancer to discover molecular targets and candidate biomarkers

1001

Advances in proteomic analysis of human samples are driving critical aspects of biomarker discovery and the identification of molecular pathways involved in disease etiology. Toward that end, in this report we are the first to utilize a standardized shotgun proteomic analysis method for in-depth tissue protein profiling of the two major subtypes of non-small cell lung cancer (NSCLC) and normal lung tissues. We identified 3621 proteins from the analysis of pooled human samples of squamous cell carcinoma, adenocarcinoma and control specimens. In addition to proteins previously shown to be implicated in lung cancer, we have identified multiple new proteins of potential interest as therapeutic targets or diagnostic biomarkers, including some that were not identified by transcriptome profiling. Up-regulation of these proteins was confirmed by multiple reaction monitoring mass spectrometry (LC-MRM-MS). This proteomic technology platform allows deep mining of lung tumor proteomes, enabling the identification of novel, previously undetected biomarker candidates and potential targets for therapy.

There are currently no biomarkers annotated for this protocol.


2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 02/12/2015

Please register for the 29th EDRN Steering Committee Meeting in Atlanta, GA from March 31-April 2, 2015. The registration page has information about booking hotel rooms and a draft agenda of the meeting.

Announcement